Shane Cooke Sells 5,000 Shares of Prothena Co. plc (NASDAQ:PRTA) Stock

Prothena Co. plc (NASDAQ:PRTAGet Rating) Director Shane Cooke sold 5,000 shares of Prothena stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $52.92, for a total transaction of $264,600.00. The transaction was disclosed in a filing with the SEC, which is available through this link.

Shane Cooke also recently made the following trade(s):

  • On Monday, December 12th, Shane Cooke sold 5,000 shares of Prothena stock. The stock was sold at an average price of $61.04, for a total transaction of $305,200.00.
  • On Thursday, November 10th, Shane Cooke sold 5,000 shares of Prothena stock. The stock was sold at an average price of $56.17, for a total transaction of $280,850.00.

Prothena Price Performance

Shares of PRTA stock opened at $56.90 on Friday. The company’s fifty day simple moving average is $58.20 and its two-hundred day simple moving average is $45.39. Prothena Co. plc has a 1 year low of $21.06 and a 1 year high of $66.47. The stock has a market capitalization of $2.75 billion, a price-to-earnings ratio of -17.04 and a beta of 0.52.

Prothena (NASDAQ:PRTAGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.66). The firm had revenue of $1.52 million for the quarter, compared to analysts’ expectations of $26.74 million. Prothena had a negative net margin of 3,036.03% and a negative return on equity of 36.46%. Equities research analysts anticipate that Prothena Co. plc will post -2.86 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PRTA. Bank of New York Mellon Corp grew its position in shares of Prothena by 1.2% during the 1st quarter. Bank of New York Mellon Corp now owns 154,281 shares of the biotechnology company’s stock valued at $5,642,000 after purchasing an additional 1,821 shares in the last quarter. HighTower Advisors LLC purchased a new position in shares of Prothena during the 1st quarter valued at $286,000. Dimensional Fund Advisors LP grew its position in Prothena by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,505,156 shares of the biotechnology company’s stock worth $55,044,000 after acquiring an additional 6,619 shares in the last quarter. First Light Asset Management LLC grew its position in Prothena by 13.3% in the first quarter. First Light Asset Management LLC now owns 1,838,548 shares of the biotechnology company’s stock worth $67,236,000 after acquiring an additional 215,607 shares in the last quarter. Finally, Mariner LLC grew its position in Prothena by 430.0% in the first quarter. Mariner LLC now owns 74,130 shares of the biotechnology company’s stock worth $2,711,000 after acquiring an additional 60,144 shares in the last quarter. 91.72% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Oppenheimer lifted their price target on shares of Prothena from $110.00 to $120.00 in a report on Tuesday, November 15th. Royal Bank of Canada cut shares of Prothena from an “outperform” rating to a “sector perform” rating and lifted their price target for the stock from $52.00 to $55.00 in a report on Friday, November 4th. They noted that the move was a valuation call. StockNews.com assumed coverage on shares of Prothena in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. TheStreet cut shares of Prothena from a “c-” rating to a “d” rating in a report on Friday, November 11th. Finally, Citigroup boosted their target price on shares of Prothena from $65.00 to $71.00 and gave the company a “buy” rating in a report on Monday, October 24th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $81.67.

Prothena Company Profile

(Get Rating)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

Featured Articles

Insider Buying and Selling by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.